The Oxford Science Park
1 Robert Robinson Avenue
About Vaccitech Limited
Vaccitech is a spin-out company from the University of Oxford’s Jenner Institute, one of the oldest and most renowned vaccine research centres in the world.
The founders of the company are Professor Adrian Hill (Director of the Jenner Institute) and Professor Sarah Gilbert (Lead in influenza and MERS), who combine their exceptional scientific skills with regulatory and manufacturing experience. The management team has decades of experience in the development of vaccine products.
Vaccitech is engaged in Phase 2 clinical programs for universal influenza and prostate cancer, Phase 1 for MERS, and preclinical programs for 3 other therapeutic infectious diseases indications. and is actively developing an internal pipeline of therapeutic candidates.
Founders: Professor Adrian Hill and Professor Sarah Gilbert
Please click here for Vaccitech's technology
Please click here for Vaccitech's job opportunities.
21 articles with Vaccitech Limited
At this time Vaccitech hasn’t priced its offering, although the report suggests they might sometime this month.
3/24/2021It’s March Madness in the life sciences industry, with money pouring in faster than LeBron James on a breakaway. Here’s where the big bucks went this week.
Future Planet Capital has invested in a $168m Series B financing announced by Vaccitech Ltd. Future Planet joins other leading investors including M&G Investment Management, Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund and fellow existing investor, Oxford Sciences Innovation.
Infectious disease-focused Vaccitech, which partnered with AstraZeneca and Oxford University on the development and manufacturing of that company’s COVID-19 vaccine, raised $168 million in a Series B financing round.
3/5/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
It was a busy week for clinical trial updates. Here’s a look.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
6/25/2020Biopharma and life sciences companies provide updates on their pipelines and business plans.
Vaccitech and Oxford University announce landmark partnership with AstraZeneca for the development and large-scale distribution of the COVID-19 vaccine candidate
Vaccitech Ltd and the University of Oxford announce an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the University.
3/26/2020Pharma and life sciences companies from across the globe provide updates on their pipelines and business practices.
12/19/2019Companies from across the globe provide updates on their business and product pipelines.
Vaccitech Oncology Limited enters collaboration with Cancer Research UK to fund a Phase I/IIa clinical trial as first-line NSCLC therapy
Vaccitech Ltd announced that its strategic collaboration with the Ludwig Institute for Cancer Research, Vaccitech Oncology Limited, has entered into a clinical partnership with Cancer Research UK to develop VOLT’s VTP-600 immunotherapy as a treatment option for patients with non-small cell lung cancer.
11/28/2019Companies from across the globe provide updates on their businesses and pipelines.
Vaccitech progresses clinical development of Universal Influenza A Vaccine (VTP-100) in Belgium and Australia and expects top-line data in early 2020
8/30/2019Biopharma companies strengthen their leadership and boards with these appointments.
Vaccitech announced that it has appointed Bill Enright as its new Chief Executive Officer.
Vaccitech Appoints Chief Medical Officer to Oversee Development of Growing Clinical Pipeline of T Cell-Inducing Viral Vector Vaccines
Mariem brings over 15 years’ experience in the Biopharmaceutical Industry, spent both advancing the clinical development and commercialisation of Infectious Disease products, and in delivering post-marketing monitoring of licensed medical products.
Vaccitech Ltd. announces that it has administered its pandemic universal influenza A vaccine MVA-NP+M1 (VTP-100) to the first participants in a Flu 010 study – a Phase 2b, randomised, double-blind, placebo controlled, influenza challenge study being conducted in Antwerp, Belgium.
The 2017/2018 influenza season was considered one of the worst, made more so by the ineffectiveness of the season’s flu vaccine. The FDA is focusing partially on simply determining why this year’s flu vaccine missed the mark.
The company says the vaccine takes a novel approach.